383P A mass spectrometry-based assay for molecular profiling of gliomas and its validation on real-world clinical samples

Abstract

Stereotaxic biopsy was performed in 17 pts (71%); 9 (53%) had grade II diffuse astrocytoma, and 3 (18%) pilocytic astrocytoma; glioblastoma (GBM) was found in 1 patient at diagnosis and in another at a late recurrence of a glial proliferation. Pons and bulb were the main sites of the tumor (N¼10/10). Among the 21 treated pts, all underwent radiotherapy (RT); 7 received sequential radiotherapy and chemotherapy (RT+CT). Median OS was 45.2 months and 5-y OS was 48.7% (95% CI 24.5-69.2%). No statistically significant association was found between OS and age, tmt modality, or MRI contrast enhancement. ECOG-PS 3-4 was identified as negative PF; although no statistically significant, there was a numerical difference of outcomes regarding histological grade (Table ).Conclusions: Diagnosis of BG using stereotaxic biopsy may be more feasible than historically assumed and diverse histologies were identified. ECOG-PS 3-4 was a negative prognostic factor. Multicenter collaborative efforts are warranted for a better evaluation of PFs, including molecular profile.Legal entity responsible for the study: The authors.